脂蛋白相关磷脂酶A2、糖化血红蛋白水平与糖尿病患者冠脉病变程度的相关性分析

陈运龙; 刘川; 刘小燕; 郭志念; 翁显贵; 王蓉; 王江

doi:10.16016/j.1000-5404.201803083

您当前的位置：

首页 >

文章列表页 >

脂蛋白相关磷脂酶A2、糖化血红蛋白水平与糖尿病患者冠脉病变程度的相关性分析

临床医学 | 更新时间：2026-01-09

- 脂蛋白相关磷脂酶A2、糖化血红蛋白水平与糖尿病患者冠脉病变程度的相关性分析
- Correlation of lipoprotein-associated phospholipase A2 and hemoglobin A1c levels with severity of coronary artery disease in diabetic patients
- 第三军医大学学报 2018年40卷第12期页码：1136-1141
- 作者机构：
  
  400037 重庆，陆军军医大学(第三军医大学)第二附属医院心血管内科, 全军心血管病研究所
- 作者简介：
  
  [ 王江，E-mail：1530579054@qq.com WANG Jiang, E-mail:1530579054@qq.com
- 基金信息：
- DOI：10.16016/j.1000-5404.201803083
  中图分类号： R446.11;R543.3;R587.2
- 收稿：2018-03-12，
  
  修回：2018-04-03，
  
  纸质出版：2018-01
- 稿件说明：
移动端阅览
陈运龙, 刘川, 刘小燕, 等. 脂蛋白相关磷脂酶A2、糖化血红蛋白水平与糖尿病患者冠脉病变程度的相关性分析[J]. 第三军医大学学报, 2018,40(12):1136-1141.

Yunlong CHEN, Chuan LIU, Xiaoyan LIU, et al. Correlation of lipoprotein-associated phospholipase A2 and hemoglobin A1c levels with severity of coronary artery disease in diabetic patients[J]. Journal of Third Military Medical University, 2018, 40(12): 1136-1141.
陈运龙, 刘川, 刘小燕, 等. 脂蛋白相关磷脂酶A2、糖化血红蛋白水平与糖尿病患者冠脉病变程度的相关性分析[J]. 第三军医大学学报, 2018,40(12):1136-1141. DOI： 10.16016/j.1000-5404.201803083.

Yunlong CHEN, Chuan LIU, Xiaoyan LIU, et al. Correlation of lipoprotein-associated phospholipase A2 and hemoglobin A1c levels with severity of coronary artery disease in diabetic patients[J]. Journal of Third Military Medical University, 2018, 40(12): 1136-1141. DOI： 10.16016/j.1000-5404.201803083.

摘要

目的

探讨脂蛋白相关磷脂酶A2(lipoprotein-associated phospholipase A2，Lp-PLA2)、糖化血红蛋白(HbA1c)水平与糖尿病患者冠脉病变程度的相关性。

方法

选取2017年7月至12月在陆军军医大学(第三军医大学)第二附属医院心血管内科住院患者241例；按冠脉狭窄程度及糖尿病病史分为冠心病组(42例)、糖尿病组(34例)、糖尿病合并冠心病组(127例)、正常对照组(38例)。按左心室射血分素(LVEF)结果分为LVEF＜50%组(91例)和LVEF≥50%(150例)。检测循环Lp-PLA2和HbA1c水平并进行统计学分析。

结果

糖尿病合并冠心病组Lp-PLA2水平显著高于糖尿病组和正常对照组(

0.05)；HbA1c在糖尿病合并冠心病组显著高于冠心病组和正常对照组(

0.05)。多元线性回归分析Lp-PLA2、HbA1c与冠脉狭窄程度(Gensini积分)正相关(

值：0.189、0.138

0.05)。多因素Logistic回归分析Lp-PLA2、HbA1c为冠脉狭窄程度的独立危险因素(

值：1.012、0.097、

0.05)。LVEF＜50%组Lp-PLA2水平显著高于LVEF≥50%组(

0.05)；HbA1c水平两组间比较差异无统计学意义(

0.05)。

结论

糖尿病合并冠心病患者循环Lp-PLA2和HbA1c水平明显升高且与冠状动脉狭窄程度呈正相关，二者联合检测对预测糖尿病患者冠脉病变程度有较好的临床价值。

Abstract

Objective

To explore the correlation of circulating lipoprotein-associated phospholipase A2 (Lp-PLA2) and hemoglobin A1c (HbA1c) levels with the severity of coronary artery stenosis in patients with type 2 diabetes mellitus (T2DM).

Methods

A total of 241 inpatients with suspected coronary artery disease (CHD) admitted in our department between July

2017 and December

2017 were enrolled in this study. According to the findings in coronary angiography

the patients were divided into CHD

T2DM

CHD with T2DM and healthy control groups. The patients were also stratified according to their left ventricular ejection fraction (LVEF) into LVEF < 50% group and LVEF≥50% group. For all the participants

circulating HbA1c level was determined with chemiluminescence detection and Lp-PLA2 level with enzyme-linked immunosorbent assay (ELISA).

Results

Lp-PLA2 level was significantly higher in diabetic patients with CHD than in those with T2DM and the healthy control subjects (

0.05). The diabetic patients with CHD also showed a significantly higher level of HbA1c than those with CHD and the control subjects (

0.05). Multivariate linear regression analysis showed that Lp-PLA2 (

=0.189

0.05) and HbA1c (

=0.138

0.05) levels were both positively correlated with the severity of coronary stenosis (Gensini score). Multivariate logistic regression analysis identified Lp-PLA2 (

=1.012

0.05) and HbA1c (

=0.097

0.05) as independent risk factors for coronary stenosis. The patients with a LVEF

50% had a significantly higher Lp-PLA2 level than those with a LVEF ≥50% (

0.05)

but their HbA1c level did not differ significantly (

0.05).

Conclusion

In diabetic patients with CHD

Lp-PLA2 and HbA1c levels are positively correlated with the severity of coronary artery stenosis

and the combined detection of Lp-PLA2 and HbA1c can be clinically informative for predicting the severity of coronary artery stenosis.

关键词

Keywords

references

SOFOGIANNI A, ALKAGIET S, TZIOMALOS K. Lipoprotein-associated phospholipase A2 and coronary heart disease[J]. Curr Pharm Des, 2018, 10. DOI: 10.2174/1381612 824666180111110550.[Epub ahead of print]

GARG P K, MCCLELLAND R L, JENNY N S, et al . Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: The multi ethnic study of atherosclerosis[J ] . Atherosclerosis, 2015, 241(1): 176-182. DOI: 10.1016/j.atherosclerosis.2015.05.006.

LI D, ZHAO L, YU J, et al . Lipoprotein-associated phospholipase A2 in coronary heart disease: review and meta-analysis[J ] . Clin Chim Acta, 2017, 465: 22-29. DOI: 10.1016/j.cca.2016.12.006.

BALLANTYNE C M, HOOGEVEEN R C, BANG H, et al . Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the atherosclerosis risk in communities (ARIC) study[J ] . Circulation, 2004, 109(7): 837-842. DOI: 10.1161/01.CIR.0000116763.91992.F1.

DANIELS L B, LAUGHLIN G A, SARNO M J, et al . Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study[J ] . J Am Coll Cardiol, 2008, 51(9): 913-919. DOI: 10. 1016/j.jacc.2007.10.048.

YANG L, LIU Y, WANG S, et al . Association between Lp-PLA2 and coronary heart disease in Chinese patients[J ] . J Int Med Res, 2017, 45(1): 159-169. DOI: 10.1177/030 0060516678145.

BENDERLY M, SAPIR B, KALTER-LEIBOVICI O, et al . Lipoprotein-associated phospholipase A2, and subsequent cardiovascular events and mortality among patients with coronary heart disease[J ] . Biomarkers, 2017, 22(3-4): 219-224. DOI: 10.3109/1354750X.2016.1171910.

ARSENAULT B J, KOHLI P, LAMBERT G, et al . Emerging cardiovascular disease biomarkers and incident diabetes mellitus risk in statin-treated patients with coronary artery disease (from the treating to new targets[TNT ] study)[J ] . Am J Cardiol, 2016, 118(4): 494-498. DOI: 10.1016/j.amjcard.2016.05.044.

MAYER O J R, SEIDLEROVá J, FILIPOVSKY J, et al . Unexpected inverse relationship between impaired glucose metabolism and lipoprotein-associated phospholipase A2 activity in patients with stable vascular disease[J ] . Eur J Intern Med, 2014, 25(6): 556-560. DOI: 10.1016/j.ejim.2014.05.010.

GARG S, MADHU S V, SUNEJA S. Lipoprotein associated phospholipase A2 activity&its correlation with oxidized LDL&glycaemic status in early stages of type-2 diabetes mellitus[J]. Indian J Med Res, 2015, 141(1): 107-114. DOI: 10.4103/0971-5916.154512.

SEYFARTH J, REINEHR T, HOYER A, et al . Lipoprotein-associated phospholipase A2 activity in obese adolescents with and without type 2 diabetes[J ] . J Inherit Metab Dis, 2018, 41(1): 73-79. DOI: 10.1007/s10545-017-0100-0.

Kotani K.Plasma lipoprotein-associated phospholipase A2 levels correlated with the cardio-ankle vascular index in long-term type 2 diabetes mellitus patients[J]. Int J Mol Sci, 2016, 17(5): pii: E634. DOI: 10.3390/ijms17050634.

JIANG J, ZHAO L, LIN L, et al . Postprandial blood glucose outweighs fasting blood glucose and HbA1c in screening coronary heart disease[J ] . Sci Rep, 2017, 7(1): 14212. DOI: 10.1038/s41598-017-14152-y.

ERTEM A G, BAǦBANCI H, KILIÇH, et al . Relationship between HbA1c levels and coronary artery severity in nondiabetic acute coronary syndrome patients[J ] . Turk Kardiyol Dern Ars, 2013, 41(5): 389-395.

WHITE H D, SIMES J, STEWART R A, et al . Changes in lipoprotein-associated ph ospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the long-term intervention with pravastatin in ischemic disease study[J ] . J Am Heart Assoc, 2013, 2(5): e000360. DOI: 10.1161/JAHA.113.000360.

SCHAEFER E J, MCNAMARA J R, ASZTALOS B F, et al . Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects[J ] . Am J Cardiol, 2005, 95(9): 1025-1032. DOI: 10.1016/j.amjcard.2005.01.023.

STABILITY INVESTIGATORS, WHITE H D, HELD C, et al . Darapladib for preventing ischemic events in stable coronary heart disease[J ] . N Engl J Med, 2014, 370(18): 1702-1711. DOI: 10.1056/NEJMoa1315878.

O'DONOGHUE M L, BRAUNWALD E, WHITE H D, et al . Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial[J ] . JAMA, 2014, 312(10): 1006-1015. DOI: 10.1001/jama.2014.11061.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

去铁胺通过降低脑铁含量抑制T1DM大鼠神经元损伤

机器人辅助左胸小切口微创冠状动脉旁路移植术的病例系列报道

冠心病患者经皮冠状动脉介入治疗术后院内心力衰竭风险预测模型的建立与验证

通过口服葡萄糖耐量试验估算平均血糖的数学模型

线粒体动力学与糖尿病并发症发病机制